Get the Stockscreener App
0.00
100.00%
-4.63
After Hours:
4.72
4.72
+
I Mab Adr stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
See More
Previous Close:
$4.63
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$533.68M
Revenue:
$3.91M
Net Income/Loss:
$-206.53M
P/E Ratio:
0.00
EPS:
-2.4825
Net Cash Flow:
$-167.78M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$6.79
I Mab Adr Stock (IMAB) Company Profile
Compare IMAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMAB
I Mab Adr
|
0.00 | 533.68M | 3.91M | -206.53M | -167.78M | -2.4825 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
I Mab Adr Stock (IMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-25 | Initiated | Leerink Partners | Outperform |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Dec-09-21 | Initiated | Siebert Williams Shank | Buy |
| Jun-02-21 | Initiated | Daiwa Securities | Buy |
| Mar-15-21 | Initiated | Needham | Buy |
| Mar-03-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-25-21 | Initiated | Piper Sandler | Overweight |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-20 | Initiated | China Renaissance | Buy |
| Feb-11-20 | Initiated | Jefferies | Buy |
View All
I Mab Adr Stock (IMAB) Latest News
Mitchells & Butlers (LON:MAB) Shares Up 7.2% – Should You Buy? - Defense World
Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer - Sahm
I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross - MSN
I-Mab (IMAB) Expected to Announce Earnings on Thursday - Defense World
Short Interest in I-Mab Sponsored ADR (NASDAQ:IMAB) Increases By 38.8% - MarketBeat
What date does NOVABRIDGE BIOS's (NBP) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
NovaBridge Biosciences (NAS:NBP) Stock News, Headlines & Updates - GuruFocus
NovaBridge Biosciences (NBP) Stock Price, Trades & News - GuruFocus
NOVABRIDGE BIOS (NBP) - Zacks Investment Research
Total assets of I-Mab Sponsored ADR – NASDAQ:NBP - TradingView
I-Mab Sponsored ADR Statistics – NASDAQ:NBP - TradingView
NBP Stock Price and Chart — NASDAQ:NBP - TradingView
NBPNovaBridge Biosciences. ADR Stock Price and Quote - Finviz
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform - Barchart.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-MabIMAB - WV News
I-Mab’s (IMAB) Buy Rating Reiterated at BTIG Research - Defense World
I-Mab Sponsored ADR (NASDAQ:IMAB) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
I-Mab stock reaffirmed as Buy at H.C. Wainwright on positive cancer drug data - Investing.com India
I-Mab stock reaffirmed as Buy at H.C. Wainwright on positive cancer drug data By Investing.com - Investing.com South Africa
I-Mab Rebrands to NovaBridge Biosciences Following Shareholder Approval - TipRanks
I-Mab reports 18% response rate for givastomig in gastric cancer trial - Investing.com India
I-Mab reports 18% response rate for givastomig in gastric cancer trial By Investing.com - Investing.com South Africa
Is Wolfspeed Inc (WOLF) positioned for future growth? - setenews.com
Using data filters to optimize entry into I Mab Depositary Receipt2025 Market Overview & Growth Focused Investment Plans - newser.com
I-Mab stock price target raised to $9 from $7 at BTIG on strategic shift - Investing.com India
I-Mab stock price target raised to $10 by Jefferies on rebranding, new asset - Investing.com India
I-Mab to rebrand as NovaBridge Biosciences, plans Hong Kong IPO - Investing.com Philippines
I-Mab (IMAB) Unveils Strategic Shift with New Business Model and Dual Listing Plan - GuruFocus
I-Mab to rebrand as NovaBridge Biosciences, plans Hong Kong IPO By Investing.com - Investing.com South Africa
I-Mab (NASDAQ:IMAB) Hits New 1-Year HighTime to Buy? - MarketBeat
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference - GlobeNewswire Inc.
I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know - MSN
Its Stock Has Paid Off Big Time For Liveperson Inc - setenews.com
Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesday - Benzinga
What Makes IMab (IMAB) a New Buy Stock - sharewise.com
I-Mab Sponsored ADR (NASDAQ:IMAB) Given Average Rating of "Buy" by Analysts - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Adversity is less terrifying than hope: Navitas Semiconductor Corp (NVTS) - setenews.com
Why Wolfspeed Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket - Benzinga
I-Mab at H.C. Wainwright Conference: Strategic U.S. Shift and Jeva Stomach Focus - Investing.com
I-Mab (NASDAQ:IMAB) Now Covered by BTIG Research - Defense World
I-Mab stock initiated with Buy rating at BTIG on gastric cancer drug potential - Investing.com
I-Mab (NASDAQ:IMAB) Receives Buy Rating from Needham & Company LLC - Defense World
I-Mab to initiate phase 2 study for gastric cancer drug in Q1 2026 - Investing.com
Adverse Reactions to Tremelimumab, Durvalumab in Liver Cancer - BIOENGINEER.ORG
C3.ai Posts Downbeat Results, Joins GitLab, Salesforce… - inkl
C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionAcadian Asset Management (NYSE:AAMI), C3.ai (NYSE:AI) - Benzinga
Equities Analysts Offer Predictions for I-Mab Q3 Earnings - MarketBeat
I-Mab stock price target raised to $8 from $6 at Brookline Capital - Investing.com
Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great Choice - Yahoo Finance
I Mab Adr Stock (IMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):